Photo of Paolo Tarantino taken from Twitter
Feb 11, 2024, 15:45
Paolo Tarantino: In a large RW cohort we found that nearly 30% of breast tumors changed HER2 status after neoadjuvant treatment
Paolo Tarantino, Medical Oncologist, Research Fellow at Dana-Farber Cancer Institute, shared a post on X/Twitter:
“In a large (≃1000) RW cohort from Dana Farber, consistently with prior reports, we found that nearly 30% of breast tumors changed HER2 status after neoadjuvant treatment. This only impacted prognosis if HER2+HER2-neg. Our latest article now out on EJC.”
Source: Paolo Tarantino/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 12:14
Nov 14, 2024, 12:09
Nov 14, 2024, 11:56
Nov 14, 2024, 11:49
Nov 14, 2024, 11:46
Nov 14, 2024, 11:38
Nov 14, 2024, 11:30